Autism Focus Lead product for Autistic Disorder is in early clinical testing, signaling a pediatric CNS opportunity. Target licensing or codevelopment with autism focused pharma, neurology portfolios, or pediatric research groups; also explore partnerships with academic consortia and patient advocacy organizations to advance trials.

Gut Brain Platform Scioto’s Activated Bacterial Therapeutics ABT platform enables delivering live bacteria to the gut with potential across GI, CNS, and oncology indications. Seek collaborations with large microbiome players to license ABT enabled products or form joint development agreements to accelerate programs and scale manufacturing.

Strategic Partnerships Past interest from global microbiome groups indicates strong external validation for partnerships and licensing. Use this momentum to structure option or exclusive licensing deals, regional partnerships, or research collaborations that provide cofunded development and access to distribution networks.

Clinical Stage Access As a clinical stage company with activity in early trials, there is opportunity to engage CROs, CMOs, and contract manufacturing networks for live biotherapeutic products. Propose trial management partnerships and manufacturing collaborations with milestone based payments to reduce upfront risk and accelerate timelines.

Funding Signals Sustained investor interest and revenue potential underscore partnership opportunities with milestone based terms and cofunding. Present as a vehicle for joint development or license deals and offer options that align with scale up and regional commercialization through partner networks.